Ewing Sarcoma of the Bone in Children under 6 Years of Age

被引:12
作者
De Ioris, Maria Antonietta [1 ]
Prete, Arcangelo [2 ]
Cozza, Raffaele [1 ]
Podda, Marta [3 ]
Manzitti, Carla [4 ]
Pession, Andrea [2 ]
Schiavello, Elisabetta [3 ]
Contoli, Benedetta [5 ]
Balter, Rita [6 ]
Fagioli, Franca [7 ]
Bisogno, Gianni [8 ]
Amoroso, Loredana [4 ]
Locatelli, Franco [1 ,9 ]
Luksch, Roberto [3 ]
机构
[1] Osped Pediat Bambino Gesu IRCCS, Haematol Oncol Dept, Rome, Italy
[2] Univ Bologna, Paediat Haematol Oncol Dept, Bologna, Italy
[3] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[4] Ist Giannina Gaslini IRCCS, Paediat Haematol Oncol Dept, Genoa, Italy
[5] Osped Pediat Bambino Gesu IRCCS, Epidemiol Unit, Rome, Italy
[6] Univ Verona, Paediat Haematol Oncol Dept, I-37100 Verona, Italy
[7] Regina Margherita Hosp, Paediat Haematol Oncol Dept, Turin, Italy
[8] Univ Padua, Paediat Haematol Oncol Dept, Padua, Italy
[9] Univ Pavia, I-27100 Pavia, Italy
关键词
PROGNOSTIC-FACTORS; FAMILY TUMORS; IFOSFAMIDE; ETOPOSIDE; CYCLOPHOSPHAMIDE; OSTEOSARCOMA; CHEMOTHERAPY; EXPERIENCE; YOUNGER; IMPACT;
D O I
10.1371/journal.pone.0053223
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Ewing Sarcoma Family Tumours (ESFT) are rare in early childhood. The aim of this study was to report the clinical characteristics and outcome of children under 6 years of age affected by ESFT of the bone in Italy. Methods: The records of all the children diagnosed with osseous ESFT in centres members of the Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP) from 1990 to 2008 were reviewed. The Kaplan-Meier method was used for estimating overall and progression-free survival (OS, PFS) curves; multivariate analyses were performed using Cox proportional hazards regression model. Results: This study includes 62 patients. An axial primary localization was present in 66% of patients, with the primary site in the chest wall in 34%. Fourteen (23%) patients presented metastatic disease. The 5-year OS and PFS were 73% (95% confidence interval, CI, 58-83%) and 72% (95% CI 57-83%) for patients with localized disease and 38% (95% CI 17-60%) and 21% (95% CI 5-45%) for patients with metastatic disease. Metastatic spread, skull/pelvis/spine primary localization, progression during treatment and no surgery predicted worse survival (P < 0.01), while patients treated in the last decade had better survival (P = 0.002). In fact, the 5-year OS and PFS for patients diagnosed in the period 2000-2008 were 89% (95% CI 71-96%) and 86% (95% CI 66-94%), respectively. Conclusion: The axial localization is the most common site of ESFT in pre-scholar children. Patients treated in the most recent period have an excellent outcome.
引用
收藏
页数:10
相关论文
共 32 条
[1]   Non-Metastatic Osteosarcoma of the Extremities in Children Aged 5 Years or Younger [J].
Abate, Massimo Eraldo ;
Longhi, Alessandra ;
Galletti, Stefano ;
Ferrari, Stefano ;
Bacci, Gaetano .
PEDIATRIC BLOOD & CANCER, 2010, 55 (04) :652-654
[2]   Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis [J].
Abudu, A ;
Mangham, DC ;
Reynolds, GM ;
Pynsent, PB ;
Tillman, RM ;
Carter, SR ;
Grimer, RJ .
BRITISH JOURNAL OF CANCER, 1999, 79 (7-8) :1185-1189
[3]  
Ahrens S, 1999, MED PEDIATR ONCOL, V32, P186, DOI 10.1002/(SICI)1096-911X(199903)32:3<186::AID-MPO5>3.0.CO
[4]  
2-D
[5]  
Bacci G, 1999, ONCOL REP, V6, P807
[6]   Ewing's sarcoma [J].
Balamuth, Naomi J. ;
Womer, Richard B. .
LANCET ONCOLOGY, 2010, 11 (02) :184-192
[7]   Ewing's sarcoma family of tumors: Current management [J].
Bernstein, Mark ;
Kovar, Heinrich ;
Paulussen, Michael ;
Randall, R. Lor ;
Schuck, Andreas ;
Teot, Lisa A. ;
Juergens, Herbert .
ONCOLOGIST, 2006, 11 (05) :503-519
[8]   Prognostic factors in Ewing's tumor of bone:: Analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study group [J].
Cotterill, SJ ;
Ahrens, S ;
Paulussen, M ;
Jürgens, HF ;
Voûte, PA ;
Gadner, H ;
Craft, AW .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3108-3114
[9]  
de Alava E, 2000, CANCER-AM CANCER SOC, V89, P783, DOI 10.1002/1097-0142(20000815)89:4<783::AID-CNCR10>3.0.CO
[10]  
2-Q